The earnings call highlights significant revenue growth and strategic progress with IBSRELA and XPHOZAH. However, challenges such as market contractions, Medicare disruptions, and increased expenses were noted. The company's strong cash position and milestone achievement in China provide additional positives.

Company Guidance -

Q1 2025

During the first quarter of 2025, Ardelyx reported a significant 61% year-over-year revenue growth, reaching $74 million. This growth was driven by robust performances from their commercial products, IBSRELA and XPHOZAH. IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by a strong prescription demand and strategic efforts to enhance prescriber adoption and patient access. The company reaffirmed its 2025 guidance of $240 million to $250 million in net sales and anticipates peak annual net sales revenue exceeding $1 billion for IBSRELA. XPHOZAH, despite market disruptions, grew by 30% from the previous year, excluding adjustments, totaling $23.4 million in net sales revenue. Ardelyx remains confident in achieving a peak sales target of $750 million for XPHOZAH, focusing on non-Medicare segments amid ongoing Medicare Part D changes. The company reported a net loss of $41.1 million and maintained a strong cash position of $214 million as of March 31, 2025.

Significant Revenue Growth

Ardelyx reported a 61% increase in revenue, totaling $74 million compared to the same period last year.

IBSRELA's Strong Performance

IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by strong prescription demand and effective commercial execution.

XPHOZAH's Growth

XPHOZAH revenue grew by 30% compared to last year, with successful patient access across Medicare and non-Medicare segments.

Financial Milestone

Ardelyx earned a $5 million milestone from their partner in China following the approval of Tenapanor for hyperphosphatemia.

Strong Cash Position

As of March 31, 2025, Ardelyx had $214 million in cash, cash equivalents, and short-term investments.

Ardelyx (ARDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 31, 2025	2025 (Q2)	-0.12 / -	-0.07	―	―	―
May 01, 2025	2025 (Q1)	-0.11 / -0.17	-0.11	-54.55% (-0.06)	―
Feb 20, 2025	2024 (Q4)	<0.01 / 0.02	-0.12	116.67% (+0.14)	―
Oct 31, 2024	2024 (Q3)	-0.05 / 0.00	0.03	―	―
Aug 01, 2024	2024 (Q2)	-0.11 / -0.07	-0.08	12.50% (<+0.01)	―
May 02, 2024	2024 (Q1)	-0.15 / -0.11	-0.13	15.38% (+0.02)	―
Feb 22, 2024	2023 (Q4)	-0.10 / -0.12	0.06	-300.00% (-0.18)	―
Oct 31, 2023	2023 (Q3)	-0.11 / 0.03	-0.14	121.43% (+0.17)	―
Aug 02, 2023	2023 (Q2)	-0.12 / -0.08	-0.19	57.89% (+0.11)	―
May 03, 2023	2023 (Q1)	-0.10 / -0.13	-0.21	38.10% (+0.08)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$5.47	$4.13	-24.50%
Feb 20, 2025	$6.36	$5.72	-10.06%
Oct 31, 2024	$5.87	$6.09	+3.75%
Aug 01, 2024	$5.50	$6.05	+10.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.